2023
Breaking through social determinants of health: Results from a feasibility study of Imani Breakthrough, a community developed substance use intervention for Black and Latinx people
Jordan A, Costa M, Nich C, Swarbrick M, Babuscio T, Wyatt J, O'Connell M, Guy K, Blackman K, Anderson R, Reis G, Ocasio L, Crespo M, Bellamy C. Breaking through social determinants of health: Results from a feasibility study of Imani Breakthrough, a community developed substance use intervention for Black and Latinx people. Journal Of Substance Use And Addiction Treatment 2023, 153: 209057. PMID: 37207836, DOI: 10.1016/j.josat.2023.209057.Peer-Reviewed Original ResearchConceptsSocial determinantsMental Health Services AdministrationDimensions of wellnessCommunity-based participatory research approachRate of deathHealth Services AdministrationDrug overdose ratesSubset of participantsSubstance use interventionsWeek 12Opioid overdoseOverdose ratesSubstance misuseEthnic disparitiesDisparity gapParticipatory research approachAddiction servicesSubstance abuseWeeks of educationHealth equityMental healthSubstance useLatinx peopleIntervention programsServices Administration
2021
Detecting change in psychiatric functioning in clinical trials for cocaine use disorder: sensitivity of the Addiction Severity Index and Brief Symptom Inventory
Kiluk BD, Roos CR, Aslan M, Gueorguieva R, Nich C, Babuscio TA, Carroll KM. Detecting change in psychiatric functioning in clinical trials for cocaine use disorder: sensitivity of the Addiction Severity Index and Brief Symptom Inventory. Drug And Alcohol Dependence 2021, 228: 109070. PMID: 34600247, PMCID: PMC8595796, DOI: 10.1016/j.drugalcdep.2021.109070.Peer-Reviewed Original ResearchConceptsAddiction Severity IndexGlobal Severity IndexPsychiatric composite scoreClinical trialsCocaine useCocaine use disorderPsychiatric functioningBrief Symptom InventorySeverity IndexUse disordersASI psychiatric composite scoreSymptom InventoryEffect sizeStart of treatmentComposite scoreClinical trial participantsWeek 12Functional outcomeTreatment periodTrial participantsPsychiatric problemsDrug usePotential functional benefitsMedium effect sizeSubstance users